In recent research, the RTK-RAS pathway was demonstrated to regulate immunotherapeutic sensitivity in glioma patients.64 Based on the mutation spectrum, we found that BAP1, COL24A1, FAT1, FBN2, and HMCN1 were potential treatment targets in MOICS1, while ATM, COL6A6, COL6A6, DST and ERBB4 were potential therapeutic targets in MOICS2. This evidence concerns the gene COL6A6 and central nervous system cancer.